—Dilip Davda
- The company is engaged in the manufacturing and marketing agrochemical and agricultural formulations.
- It currently operates in 8 states and has 685 distributors.
- The company is operating in a highly competitive and fragmented segments.
- Based on its recent average financial data, the issue appears fully priced.
- Merchant Banker has a poor track record.
- There is no harm in skipping this small fully priced offer.
ALERT: IN VIEW OF THE LIKELY BANK STRIKE FROM 28.09.26 TO 30.09.26, THE IPOS/PRIMARY OFFERS THAT ARE FALLING BETWEEN THESE THREE DAYS, IPOS SCHEDULE TIME LINE MAY CHANGE AND THE REVISED DATES WILL GET EFFECTIVE FOR OPENING AND / OR CLOSING SCHEDULES, AS THE CASE MAY BE. INVESTORS ARE REQUESTED TO MAKE A NOTE OF THIS.
ABOUT COMPANY:
Shivchem Agro Ltd. (SAL) is ISO 9001:2015, ISO 22000:2018 and ISO 31000:2018 certified agrochemical company operating in India, engaged in the manufacturing, stocking, exhibiting, distribution, and sale of agricultural formulations. Its product portfolio includes insecticides, fungicides, herbicides, plant growth regulators, rodenticides, and fertilizers.
It provides customers with crop protection solutions designed to support farmers in agricultural output through manufacturing, supply and distribution of formulations. These Formulations may be in the form of solids (e.g., powders) or liquids (e.g., emulsifiable concentrates). The Company is required to obtain various licenses and permissions from various authorities for manufacturing and sale of products. During the financial year 2023-24, it had licenses for manufacturing 232 agrochemical products which expanded to 258 licenses in the financial year 2024–25. With an objective to offer a wide product portfolio, SAL continuously works to expand range of agrochemical products.
As on the date of this Red Herring Prospectus, it had license under the Insecticides Act, 1968 for manufacturing 176 agrochemical products including 88 insecticides, 40 fungicides, 37 herbicides, 8 plant growth regulators and 3 rodenticides. These registrations are granted by the Central Insecticides Board and Registration Committee (CIBRC), Directorate of Plant Protection, Quarantine & Storage, under the Department of Agriculture & Farmers Welfare, Haryana. In addition, it has Letter of Authorization from the Agriculture and Farmers Welfare Department, Haryana, Panchkula, for the manufacturing of 82 fertilizers under the Fertilizer Control Order, 1985.
SAL is licensed to sell, stock, exhibit and distribute products in eight (8) states of India, namely, Andhra Pradesh, Telangana, Odisha, Assam, Bihar, West Bengal, Uttar Pradesh and Madhya Pradesh. As of March 31, 2026, it had 685 distributors selling its products across the aforementioned states. For supply and distribution to these distributors, it operates five (5) godowns in the aforementioned states. As of March 31, 2026, it had 66 employees on its payroll, and 685 distributors.
ISSUE DETAILS/ CAPITAL HISTORY:
The company is coming out with its maiden book building route IPO of 2260000 equity shares of Rs. 5 each to mobilize Rs. 14.01 cr. at the upper cap. The company has announced a price band of Rs. 59 – Rs. 62 per share. The minimum application to be made is for 4000 shares and in multiples of 2000 shares thereon, thereafter. The issue opens for subscription on September 28, 2026 and will close on September 30, 2026. The shares will be listed on BSE SME. The IPO constitute 30.00% of the post-IPO paid-up capital of the company. From the net proceeds of the issue, the company will utilize Rs. 6.90 cr. for working capital, Rs. 3.50 cr. for debt repayment, and the rest for general corporate purposes.
The IPO is solely lead managed by Shannon Advisors Pvt. Ltd., while Maashitla Securities Pvt. Ltd. is the registrar to the issue. Nikunj Stock Brokers Ltd. is a market maker. The IPO is underwritten 50% each, by Shannon Advisors and Fincos Technology Solutions Pvt. Ltd.
After issuing initial equity capital at par value, the company issued/converted further equity shares in the price range of Rs. 9.58 – Rs. 44.00 per share (based on Rs. 5 FV) between October 2024, and February 2025. It has also issued bonus shares in the ratio of 14 for 1 in September 2024. The average cost of the acquisition of shares by the promoters is Rs. 6.63 per share.
Post-IPO, company’s current paid-up equity capital of Rs. 2.64 cr. (5272873 equity shares) will stand enhanced to Rs. 3.77 cr. (7532873 equity shares). Based on the upper band of the IPO pricing, the company is looking for a market cap of Rs. 46.70 cr.
FINANCIAL PERFORMANCE:
On the financial performance front, for the last three fiscals, the company has posted total income/ net profit, of Rs. 10.95 cr. / Rs. 1.29 cr. (FY24), Rs. 27.50 cr. / Rs. 2.60 cr. (FY25), Rs. 33.84 cr. / Rs. 3.25 cr. (FY26). The company posted steady growth in its top and bottom lines for the reported periods. Rising trade receivables year-on-year, raise alarms. For FY26, its trade receivables stood at Rs. 16.94 cr. against the revenue of Rs. 33.84 cr. and an equity capital base of Rs. 2.64 cr.
For the last three fiscals, the company has reported an average EPS of Rs. 8.50 and an average RoNW of 55.13%. The issue is priced at a P/BV of 2.53 based on its NAV of Rs. 24.50 per share as of March 31, 2026, but its post-IPO NAV data is missing from the offer documents.
If we attribute FY26 earnings to its post-IPO fully diluted paid-up equity capital, then the asking price is at a P/E of 14.39, and based on FY25 earnings, the P/E stands at 17.97. The issue appears fully priced based on its recent average earnings.
The company has posted PAT Margins of 11.82% (FY24), 9.47% (FY25), 9.61% (FY26) and RoCE margins of 37.55%, 31.99%, 30.04%, respectively for referred periods.
DIVIDEND POLICY:
The company has not paid any dividends for the reported periods of the offer document. It has already adopted a dividend policy in June 2025, based on its financial performance and future prospects.
COMPARISON WITH LISTED PEERS:
As per the offer document, the company has shown Super Crop, Sikko Ind., as its listed peers. They are currently trading at a P/E of 32.0, and 47.0 (as of September 25, 2026). However, they are not truly comparable on an apple-to-apple basis. This comparison appears to be an eye-wash.
MERCHANT BANKER’S TRACL RECORD:
Surprisingly, the merchant banker has suppressed the info on its past mandates, and urged to refer its website for the details. Is this kind of disclosure allowed by SEBI???
Based on information in its recent issue of Sai Urja RHP, following information is compiled:
This is the 4th mandate from Shannon Advisors, in the last two fiscals (including the ongoing one). Out of the last 2 listings, both opened at discount on the listing date. The merchant banker has very poor track record.
CONCLUSION:
SAL is engaged in the manufacturing and marketing agrochemical and agricultural formulations. It currently operates in 8 states and has 685 distributors. The company is operating in a highly competitive and fragmented segments. Tiny post-IPO equity capital indicates longer gestation for migration. Based on its recent average financial data, the issue appears fully priced. Merchant Banker has a poor track record. There is no harm in skipping this small issue.
Review By Dilip Davda on August, 2026
Review Author
DISCLAIMER: No financial information whatsoever published anywhere here should be construed as an offer to buy or sell securities, or as advice to do so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions. My reviews do not cover GMP market and operators game plans. Readers must consult a qualified financial advisor before making any actual investment decisions, based the on information published here. With entry barriers, SEBI wants only well-informed investors to participate in such offers. With crazy listings in the recent past, SME IPOs drew the attention of investors across the board and lead to seer madness. However, as SME issues have entry barriers and continued low preference from the broking community, any reader taking decisions based on any information published here does so entirely at their own risk. The above information is based on information available as of date coupled with market perceptions. The Author has no plans to invest in this offer.
About Dilip Davda
Dilip Davda is veteran journalist associated with stock market since 1978. He is contributing to print and electronic media on stock markets/insurance/finance since 1985.
Dilip Davda is a leading reviewer of public issues and NCDs in the primary stock market in India. The knowledge he gained over 3 decades while working in the stock market and a strong relationship with popular lead managers makes his reviews unique. His detailed fundamental and financial analysis of companies coming up with IPOs helps investors in the primary stock market. Dilip Davda has a special interest in analyzing the SME companies and writing reviews about their public issues. His reviews are regularly published online and in news papers.
(Dilip Davda -SEBI registered Research Analyst-Mumbai,
Registration no. INH000003127 (Perpetual)
Email id: dilip_davda@rediffmail.com ).
